Next Article in Journal
Synthesis and Evaluation of Saccharide-Based Aliphatic and Aromatic Esters as Antimicrobial and Antibiofilm Agents
Next Article in Special Issue
Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review
Previous Article in Journal
Higher S100B Levels Predict Persistently Elevated Anhedonia with Escitalopram Monotherapy Versus Antidepressant Combinations: Findings from CO-MED Trial
Previous Article in Special Issue
A Decade of Antifungal Leads from Natural Products: 2010–2019
Communication

Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-f]quinazolin-9(8H)-one, a Promising Inhibitor of DYRK1A

1
Normandie Univ, UNIROUEN, INSA Rouen, CNRS, COBRA UMR 6014, 76000 Rouen, France
2
Department of Medicine, Division of Hematology/Oncology, Northwestern University, Chicago, IL 60611, USA
3
College of Medicine, University of Illinois, Chicago, IL 60611, USA
4
ManRos Therapeutics & Perha Pharmaceuticals, Perharidy Peninsula, 29680 Roscoff, France
5
Department of Biochemistry and Molecular Genetics, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2019, 12(4), 185; https://0-doi-org.brum.beds.ac.uk/10.3390/ph12040185
Received: 18 October 2019 / Revised: 13 December 2019 / Accepted: 14 December 2019 / Published: 17 December 2019
Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) hyperactivity has been linked to the development of a number of human malignancies. DYRK1A is the most studied family member, and the discovery of novel specific inhibitors is attracting considerable interest. The 8-cyclopropyl-2(pyridin-3-yl)thiazolo[5,4-f]quinazolin-9(8H)-one (also called FC162) was found to be a promising inhibitor of DYRK1A and was characterized in biological experiments, by western transfer and flow cytometry on SH-SY5Y and pre-B cells. Here, the results obtained with FC162 are compared to well-characterized known DYRK1A inhibitors (e.g., Leucettine L41 and EHT1610). View Full-Text
Keywords: thiazolo[5,4-f]quinazolin-9(8H)-one; CMGC kinases; DYRK family kinases; SH-SY5Y-Tau-4R cells; pre-B cells; quiescence thiazolo[5,4-f]quinazolin-9(8H)-one; CMGC kinases; DYRK family kinases; SH-SY5Y-Tau-4R cells; pre-B cells; quiescence
Show Figures

Graphical abstract

MDPI and ACS Style

Fruit, C.; Couly, F.; Bhansali, R.; Rammohan, M.; Lindberg, M.F.; Crispino, J.D.; Meijer, L.; Besson, T. Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-f]quinazolin-9(8H)-one, a Promising Inhibitor of DYRK1A. Pharmaceuticals 2019, 12, 185. https://0-doi-org.brum.beds.ac.uk/10.3390/ph12040185

AMA Style

Fruit C, Couly F, Bhansali R, Rammohan M, Lindberg MF, Crispino JD, Meijer L, Besson T. Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-f]quinazolin-9(8H)-one, a Promising Inhibitor of DYRK1A. Pharmaceuticals. 2019; 12(4):185. https://0-doi-org.brum.beds.ac.uk/10.3390/ph12040185

Chicago/Turabian Style

Fruit, Corinne; Couly, Florence; Bhansali, Rahul; Rammohan, Malini; Lindberg, Mattias F.; Crispino, John D.; Meijer, Laurent; Besson, Thierry. 2019. "Biological Characterization of 8-Cyclopropyl-2-(pyridin-3-yl)thiazolo[5,4-f]quinazolin-9(8H)-one, a Promising Inhibitor of DYRK1A" Pharmaceuticals 12, no. 4: 185. https://0-doi-org.brum.beds.ac.uk/10.3390/ph12040185

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop